Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy

Annals of Oncology

Volumn 22, Issue 10, 2011, Pages 2250-2256

  Klaver, Y L B ^a   Lemmens, V E P P ^b   Creemers, G J ^a   Rutten, H J T ^a   Nienhuijs, S W ^a   de Hingh, I H J T ^a  

^a CATHARINA HOSPITAL   (Netherlands)

^b Eindhoven Cancer Registry   (Netherlands)

Author keywords

Colorectal cancer; Metastasis; Palliative chemotherapy; Peritoneal carcinomatosis; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEASONAL VARIATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TREND STUDY;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASMS, MULTIPLE PRIMARY; NETHERLANDS; PALLIATIVE CARE; PERITONEAL NEOPLASMS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 80053137627     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq762     Document Type: Article

References (29)

1. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
2. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
3. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
4. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
5. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705.
6. Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141: 586-589.
7. Chu DZ, Lang NP, Thompson C et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989; 63: 364-367.
8. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: 1545-1550.
9. Sadeghi B, Arvieux C, Glehen O et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88: 358-363.
10. Schouten LJ, Hoppener P, van den Brandt PA et al. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 1993; 22: 369-376.
11. Lemmens VE, Klaver YL, Verwaal VJ et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2010; In press.
12. Lemmens VE, van Steenbergen L, Janssen-Heijnen M et al. Trends in colorectal cancer in the south of the Netherlands 1975-2007: rectal cancer survival levels with colon cancer survival. Acta Oncol 2010; 49: 784-796.
13. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
14. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
15. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
16. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
17. Jonker DJ, Maroun JA, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br J Cancer 2000; 82: 1789-1794.
18. Folprecht G, Köhne CH, Lutz MP et al. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Cancer Treat Res 2007; 134: 425-440.
19. Elias D, Lefevre JH, Chevalier J et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27: 681-685.
20. Meulenbeld HJ, van Steenbergen LN, Janssen-Heijnen ML et al. Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004. Ann Oncol 2008; 19: 1600-1604.
21. Baskaratan S, Philips J, McCredden P, Solomon MJ. Free colorectal cancer cells on the peritoneal surface: correlation with pathologic variables and survival. Dis Colon Rectum 2004; 47: 2076-2079.
22. Varghese S, Burness M, Xu H et al. Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. Ann Surg Oncol 2007; 14: 3460-3471.
23. Kotanagi H, Saito Y, Yoshioka T, Koyama K. Characteristics of two cancer cell lines derived from metastatic foci in liver and peritoneum of a patient with colon cancer. J Gastroenterol 1998; 33: 842-849.
24. Rekhraj S, Aziz O, Prabhudesai S et al. Can intra-operative intraperitoneal free cancer cell detection techniques identify patients at higher recurrence risk following curative colorectal cancer resection: a meta-analysis. Ann Surg Oncol 2008; 15: 60-68.
25. Fermor B, Umpleby HC, Lever JV et al. Proliferative and metastatic potential of exfoliated colorectal-cancer cells. J Natl Cancer Inst 1986; 76: 347-349.
26. McHugh SM, O'Donnell J, Gillen P. Genomic and oncoproteomic advances in detection and treatment of colorectal cancer. World J Surg Oncol 2009; 7: 36.
27. Del Rio M, Molina F, Bascoul-Mollevi C et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 2007; 25: 773-780.
28. Gout S, Huot J. Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron 2008; 1: 69-83.
29. Verwaal VJ, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743.